

October 28, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Board of Directors of the Company at its meeting held today i.e., on October 28, 2025, has noted/ approved the following:

- a) Noted the resignation of Dr. V Prasada Raju (DIN: 07267366), as Managing Director and Director of the Company. In view of his resignation, he will cease to be a Director and Key Managerial Personnel, with effect from close of business hours on October 28, 2025. However, he will continue to be available with the Company in terms of his contractual terms with the Company and to facilitate seamless transition of his duties and responsibilities.

The Board placed on record its appreciation for the valuable contribution made by Dr. V Prasada Raju during his tenure on the Board.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject and the resignation email dated October 24, 2025 along with reasons for the resignation, as received from Dr. V Prasada Raju are annexed herewith.

- b) Based on the recommendations of the Nomination and Remuneration Committee, approved the appointment of Mr. Himanshu Agarwal (DIN: 06672915), presently designated as Chief Financial Officer, as an Additional Director of the Company, for a period of 5 (five) years with effect from October 29, 2025, designated as Whole-time Director and Chief Financial Officer of the Company. The appointment of Mr. Himanshu Agarwal will be subject to approval of the shareholders of the Company through postal ballot process. The brief profile of Mr. Himanshu Agarwal is annexed with this disclosure.

Mr. Himanshu Agarwal is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



- c) Pursuant to Regulation 30(5) of the SEBI Listing Regulations, approved revisions to the authorized Key Managerial Personnel for the purpose of determining materiality of an event or information and making disclosures thereof to the Stock Exchange(s). The “Policy for Determining Material Event or Information” (“Policy”) in pursuance to Regulation 30 of the SEBI Listing Regulations, is also amended to reflect the above change under Regulation 30(5) of SEBI Listing Regulations. The changes will be effective from October 29, 2025:

| Name | Designation | E-mail ID |
|----------------------|--|--|
| Mr. Vivek Sharma | Executive Chairman | vsharma@cohance.com |
| Mr. Himanshu Agarwal | Whole-time Director and Chief Financial Officer (<i>Whole-time Director with effect from October 29, 2025</i>) | himanshu.agarwal@cohance.com |
| Mr. Kundan Kumar Jha | Company Secretary, Compliance Officer and Head-Legal | kundankumar.jha@cohance.com |

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above



Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

| | Name of Person | Dr. V Prasada Raju | Mr. Himanshu Agarwal |
|---|---|---|--|
| 1 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise | Resignation of Dr. V Prasada Raju (DIN: 07267366) as Managing Director and Director, effective from close of business hours on October 28, 2025. The resignation letter received from Dr. V Prasada Raju is annexed herewith. | Appointment of Mr. Himanshu Agarwal (DIN: 06672915) as Additional Director and Whole-Time Director of the Company with effect from October 29, 2025, subject to approval of the shareholders of the Company. Consequently, he will be designated as Whole-time Director and Chief Financial Officer of the Company |
| 2 | Date of appointment / re-appointment / cessation (as applicable) and term of appointment / re-appointment | Resignation of Dr. V Prasada Raju as Managing Director and Director, effective from close of business hours on October 28, 2025. | Appointment of Mr. Himanshu Agarwal as Additional Director and Whole-Time Director of the Company, with effect from October 29, 2025. |
| 3 | Brief profile (in case of appointment) | Not applicable | Enclosed. |
| 4 | Disclosure of relationship between directors (in case of appointment of a director) | Not applicable | Mr. Himanshu Agarwal is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. |

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



Profile of Mr. Himanshu Agarwal



Himanshu is finance professional with professional degrees from the Institute of Chartered Accountants of India, Institute of Cost and management Accountants of India and Institute of Company Secretaries of India.

He has been associated with the Company as CFO from January 2, 2024.

He started his professional career in 1991 and in his over 30 years of work experience has worked across multiple countries, locations and finance profiles and has gathered a wide and diversified view of business and finance.

Before Joining Cohance, he has worked with MNC's like ICI India, Huhtamaki oyj, and earlier CFO and Whole-time director of AkzoNobel India and as the CFO of Astra Zeneca Pharma Ltd, Bennett, Coleman & Co.

He was awarded the Best CFO by the Institute of Chartered Accountants of India.



Kundan Kumar Jha

Subject: FW: Resignation from the Position of Managing Director

From: Dr. PrasadaRaju.V <drprasadaraju.v@cohance.com>

Date: Friday, 24 October 2025 at 12:39 AM

To: Vivek Sharma <vsharma@cohance.com>

Subject: Resignation from the Position of Managing Director

Dear Vivek,

After careful consideration of my personal priorities and to continue my learning journey, I hereby resign from the position of Managing Director of Cohance Life Sciences. This resignation will be effective from the date on which it is taken on record by the board of directors and as notified by the company to me.

I remain committed to ensuring a smooth and orderly transition during the notice period.

Serving Cohance has been an honour and a privilege. Over the years, I have been fortunate to work alongside an exceptional, self-driven team and contribute to the co-creation of Cohance, a global technology-led CDMO and API+ Organisation.

I deeply value the trust and confidence that the Board, Cohancers, Investors, Business partners, Operating Partners, and Advisory Council have placed in me during my tenure.

I leave with immense pride in what we have achieved together from ground zero and great confidence in the Organisation's future.

Yours sincerely,

Prasada Raju
Managing Director

The logo for Cohance, featuring the word "Cohance" in a sans-serif font. The "Co" is in blue, and "hance" is in a darker blue. The "o" in "Co" has a yellow-to-orange gradient.

Cohance Lifesciences Limited.

Corp. Office 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City,
TSIIC, Raidurg, Hyderabad - 500081, Telangana, India.

www.cohance.com